[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"edema-leg\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:edema-leg":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100638885","extracorporeal-shock-wave-therapy-in-lower-extremity-lymphedema-100638885",false,"NCT07626645","Extracorporeal Shock Wave Therapy in Lower Extremity Lymphedema","Efficacy of Extracorporeal Shock Wave Therapy (ESWT) in Lower Extremity Lymphedema: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to 80 years\n* Clinical diagnosis of lower extremity lymphedema established at least 6 months prior to enrollment\n* Completion of at least one cycle of CDT Phase 1 (intensive decongestive phase) within the preceding six months\n* Currently in CDT Phase 2 (maintenance phase) with active use of compression garments\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Active chemotherapy or radiotherapy\n* Active infection\n* Lower extremity vascular diseases including deep vein thrombosis or arterial insufficiency\n* Presence of a cardiac pacemaker\n* Pregnancy\n* Bleeding disorders","ALL","18 Years","80 Years",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","Lower extremity lymphedema is a chronic and progressive condition associated with significant functional impairment and reduced quality of life. The current gold-standard treatment is Complex Decongestive Therapy (CDT); however, a substantial proportion of patients continue to experience persistent symptoms during the maintenance phase. This prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effectiveness of Extracorporeal Shock Wave Therapy (ESWT) as an adjunct to standard CDT maintenance therapy in patients with lower extremity lymphedema. Participants will be randomly allocated to either an active ESWT group or a sham ESWT group, with both groups continuing standard CDT maintenance throughout the study. ESWT will be administered twice weekly for five sessions. Changes in limb volume, skin thickness and subcutaneous tissue thickness assessed by ultrasonography, pain, functional status, and quality of life will be evaluated at baseline, after treatment, and at one-month follow-up.",[27,28,29,30,31],"Lymphedema, Lower Limb","Extracorporeal Shock Wave Therapy","Edema Leg","Sham-controlled","Placebo Control Design",[33,34,35,36,37,38,39],"Lower Extremity Lymphedema","Extracorporeal Shock Wave Therapy (ESWT)","Complex Decongestive Therapy (CDT)","Limb Volume","Ultrasonography","skin and subcutaneous tissue thickness","Quality of Life","NOT_YET_RECRUITING","2026-06-02",{"date":43,"type":44},"2026-06-04","ACTUAL",{"date":46,"type":21},"2026-06-22",{"date":48,"type":21},"2027-02-01",{"name":50,"class":51},"Gazi University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":52},"100527862","does-edema-affect-the-adjustment-of-tens-amplitude-100527862","NCT06153277","Does Edema Affect the Adjustment of TENS Amplitude","Does Edema After Knee Arthroplasty Affect the Adjustment of TENS Amplitude","Inclusion Criteria:\n\n* Age ≥ 40 years\n* Patients undergoing unilateral total knee arthroplasty\n\nExclusion Criteria:\n\n* Patients with scars in any of both knee areas\n* Patients who have previously had surgery on the control leg\n* Patients undergoing surgery due to trauma or cancer\n* Patients with sensory impairments\n* Patients with excessive effusion and edema in the knee joints before the surgery (eg. Inflammatory arthropathy, gonarthrosis exacerbation, etc.)\n* Mental impairment, or poor general health status that would interfere with assessments during TENS application.\n* Any contraindication for TENS (allergy to the TENS electrodes, skin conditions or skin sensation impairment in the areas where the electrodes will be placed, pacemaker or other implanted electrical device, epilepsy, pregnancy)","40 Years",{"count":62,"type":21},125,"OBSERVATIONAL","The goal of this pre-post clinical trial is to compare the amplitude settings of three different frequency TENS modes (Conventional TENS, LF TENS, HF TENS) in patients who had undergone total knee arthroplasty, both with the preoperative state and with the contralateral knee. The main question it aims to answer is: Can the electrical resistance of edematous tissue be affected and change the TENS amplitude setting? Participants will be evaluated before and after surgery. For each TENS modulation the amplitude at which tingling is felt, the current is clearly felt, and is maximum tolerated and\u002For muscle contraction occurred, will be documented. TENS amplitudes for all three TENS modes will be compared, both with the preoperative state and with the contralateral knee.",[29,66],"Pain",[68,69,70],"Transcutaneous electrical nerve stimulation","Amplitude adjustment","Arthroplasty","RECRUITING","2025-12-04",{"date":74,"type":44},"2025-12-11",{"date":76,"type":44},"2023-12-07",{"date":78,"type":21},"2026-04",{"name":80,"class":51},"Karamanoğlu Mehmetbey University",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100567618","phase-2-a-dose-finding-study-of-jmkx003142-in-treatment-of-renal-edema-100567618","NCT06670534","A Dose-finding Study of JMKX003142 in Treatment of Renal Edema","A Multicenter,Randomized,Open-label,Positive-controlled Study to Evaluate the Efficacy and Safety of JMKX003142 in Renal Edema Patients","Inclusion Criteria:\n\n* Patients who can fully understand the purpose and process of the study and voluntarily sign the informed consent form（ICF）;\n* Age ≥ 18 years old during screening;\n* Diagnosed as renal edema during screening;\n* Estimated glomerular filtration rate（eGFR） ≥ 15 mL\u002Fmin\u002F1.73m2 during screening.\n\nExclusion Criteria:\n\n* Patients who are receiving the renal replacement therapy during screening or patients who require renal replacement therapy in the short term evaluated by the researchers;\n* Patients who are suspected with hypovolemia;\n* Patients with the following diseases or symptoms: acute thrombosis, diarrhea, and difficulty urinating;\n* Patients who are unable to sense thirst or who have difficulty with fluid intake;\n* Patients who have received arginine vasopressin-V2R blockers within 30 days prior to the screening examination;\n* The following laboratory indicators are abnormal: glutamic pyruvic transaminase ≥ 1.5 ×upper limit of normal, glutamic oxaloacetic transaminase ≥ 1.5 × upper limit of normal, serum sodium\\> upper limit of normal, D-dimer ≥ 2 × upper limit of normal;\n* Patients who received diuretics or treatments with diuretic effects from Day-2 to randomization;\n* During screening, systolic blood pressure \\\u003C90mmHg\u002Fdiastolic blood pressure\\\u003C60mmHg, systolic blood pressure\\>160mmHg\u002Fdiastolic blood pressure \\>100mmHg;\n* Patients who have a history of allergies to ≥ 3 substances, or are currently in an allergic state;\n* Female patients who are breast-feeding or who have a positive pregnancy test result prior to receiving investigational product (IMP);\n* Sexually active males or women of childbearing potential (WOCBP) who do not agree to practice birth control or remain abstinent during the trial and for 30 days after the final IMP administration.",{"count":89,"type":21},216,[91],"PHASE2","To Evaluate the Safety, Efficacy, and Pharmacokinetic Characteristics of JMKX003142 Administered Randomly, Open-label, Active-controlled Study in Chinese Renal Edema Patients.",[94,29],"Edema Secondary",[96,97],"renal edema","edema due to kidney diseases","2025-08-07",{"date":100,"type":44},"2025-08-12",{"date":102,"type":44},"2025-01-07",{"date":104,"type":21},"2026-07-30",{"name":106,"class":107},"Jemincare","INDUSTRY",2]